PharmaCyte Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of PharmaCyte Biotech generated cash of -$2,151,457, which is more than the previous year. Cash used in financing activities reached the amount of -$10,708,003 last year. Net change in cash is therefore -$17,859.
Cash Flow
| 2015 | -4.56M | 0 | 3.64M |
|---|---|---|---|
| 2016 | -4.34M | 0 | 3.56M |
| 2017 | -3.33M | 0 | 4.88M |
| 2018 | -5.07M | 0 | 2.68M |
| 2019 | -2.87M | 0 | 2.34M |
| 2020 | -2.33M | 0 | 2.72M |
| 2021 | -3.33M | 0 | 4.63M |
| 2022 | -4.11M | 0 | 87.31M |
| 2023 | -3.79M | 0 | -13.55M |
| 2024 | -2.15M | -5M | -10.70M |
PMCB Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 68.03M | 85.40M | 2.20M | 894.86K | 515.25K | 1.05M | 3.46M | 1.92M | 2.69M | 3.61M |
Operating activities | ||||||||||
Net income | 333.76K | -4.31M | -4.23M | -3.55M | -3.82M | -4.06M | -6.82M | -4.44M | -6.06M | -10.85M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 674 | 645.40K | 77.95K | 370.82K | 748.02K | 705.67K | 1.52M | 1.01M | 2.09M | 6.20M |
| Deferred income tax benefit | 674 | 645.40K | 77.95K | 370.82K | 748.02K | 705.67K | 1.52M | 1.01M | 2.09M | 6.20M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 261.09K | -242.94K | 33.1K | -13.58K | 63.95K | -230.73K | -12.97K | 29.59K | -160.69K | 308.65K |
Cash generated by operating activities | -2.15M | -3.79M | -4.11M | -3.33M | -2.33M | -2.87M | -5.07M | -3.33M | -4.34M | -4.56M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 87.36M | 4.69M | 2.66M | 2.34M | 2.68M | 4.88M | 3.56M | 3.78M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -44.35M | -13.56M | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -62.44K | -12.35K | 0 | 0 | 0 | 0 | -143.85K |
Cash used in financing activities | -10.70M | -13.55M | 87.31M | 4.63M | 2.72M | 2.34M | 2.68M | 4.88M | 3.56M | 3.64M |
Net Change In Cash | -17.85K | -17.36M | 83.19M | 1.30M | 379.60K | -544.54K | -2.40M | 1.54M | -778.91K | -916.73K |
Cash at end of period | 50.17M | 68.03M | 85.40M | 2.20M | 894.86K | 515.25K | 1.05M | 3.46M | 1.92M | 2.69M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |